TY - JOUR T1 - Pretargeted Imaging and Therapy JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1553 LP - 1559 DO - 10.2967/jnumed.117.189944 VL - 58 IS - 10 AU - Mohamed Altai AU - Rosemery Membreno AU - Brendon Cook AU - Vladimir Tolmachev AU - Brian M. Zeglis Y1 - 2017/10/01 UR - http://jnm.snmjournals.org/content/58/10/1553.abstract N2 - In vivo pretargeting stands as a promising approach to harnessing the exquisite tumor-targeting properties of antibodies for nuclear imaging and therapy while simultaneously skirting their pharmacokinetic limitations. The core premise of pretargeting lies in administering the targeting vector and radioisotope separately and having the 2 components combine within the body. In this manner, pretargeting strategies decrease the circulation time of the radioactivity, reduce the uptake of the radionuclide in healthy nontarget tissues, and facilitate the use of short-lived radionuclides that would otherwise be incompatible with antibody-based vectors. In this short review, we seek to provide a brief yet informative survey of the 4 preeminent mechanistic approaches to pretargeting, strategies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, and bioorthogonal click chemistry. ER -